v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 2,842,728 $ 3,135,427
General and administrative 1,229,807 1,369,215
Loss on early termination of vendor agreement   453,135
Total operating expenses 4,072,535 4,957,777
Loss from operations (4,072,535) (4,957,777)
Other income:    
Grant income 751,691 349,104
Interest income 132,889 162,489
Other income 8,677  
Net loss $ (3,179,278) $ (4,446,184)
Net loss per share:    
Net loss per share, basic (in dollars per share) $ (0.16) $ (0.4)
Net loss per share, diluted (in dollars per share) $ (0.16) $ (0.4)
Weighted average number of common shares outstanding:    
Basic (in shares) 19,314,742 11,106,027
Diluted (in shares) 19,314,742 11,106,027